Why Temporary Schedule I Placement Is the Wrong Approach for 7-OH

The Drug Enforcement Administration (DEA) wants to place products containing 7-hydroxymitragynine (7-OH) above a proposed limit on Schedule I of the Controlled Substances Act—the strictest category under federal drug law.  A derivative of kratom tree leaves, 7-OH acts on some of the same brain receptors as opioids and can produce tolerance, dependence, and withdrawal with frequent use of concentrated products. The question is not whether 7-OH has risks, but whether prohibition will reduce those risks more than regulation would. Once the DEA’s new rule takes effect, selling or possessing a covered product without federal authorization could bring criminal penalties. Additionally, Schedule I status hinders research by imposing bureaucratic hurdles and discouraging funding—both of which come with unintended consumer-safety consequences. Rather than enacting a hasty ban, the DEA should move at a pace that allows the exploration of medical and safety questions to help determine the most appropriate regulation.

A review of kratom research found major gaps in safety data, patterns of use, and product testing—information agencies need in order to set sound limits for dose, purity, and labeling. Yet, stricter scheduling would make 7-OH harder to study. Researchers may study Schedule I substances, but they face extra federal requirements for registration, research plans, storage, recordkeeping, and access to study material. Studies of cannabis and psychedelics found that these rules delayed projects, raised costs, and restricted research materials.

Because no study has yet measured what a federal 7-OH ban would do to consumers or sellers, its effect on an illegal market is unknown. A systematic review found that 14 of 15 studies linked stronger drug-law enforcement with more violence in illegal markets. State comparisons found fewer reported kratom poisonings and kratom-positive overdose deaths in ban states, though studies could not prove the bans were responsible for these differences and did not measure illegal sales, arrests, or substance switching. This is why researching the impact of bans and their long-term effects is important prior to any scheduling consideration.

The effect of criminalization on consumers is clearer. The DEA states that unauthorized possession, manufacture, or sale of covered products would be subject to federal civil and criminal controls. Users, especially those who interact with law enforcement, often face problems with employment, housing, family stability, and healthcare access. This means people who now buy 7-OH legally for pain, withdrawal, or other personal reasons could face prosecution. Instead, consumers should receive better information about product contents. Sellers outside the law would have little reason to verify age, use accurate labels, test each batch, report harmful events, or recall defective products.

Worse, federal history calls the word “temporary” into question. In 2011, the DEA temporarily placed five synthetic cannabinoids as well as three synthetic cathinones into Schedule I. By 2013, all had become permanent Schedule I drugs. A two-year temporary order for fentanyl-related substances began in 2018; Congress extended it 10 times before permanently placing the class into Schedule I in 2025. These examples do not prove that every temporary order becomes permanent; instead, they show that an expiration date does not guarantee the end of tighter control.

While the current 7-OH market has real problems, they point toward a need for product rules rather than sweeping bans. One laboratory study found that more than 98 percent of tested 7-OH products were semisynthetic, meaning manufacturers chemically converted kratom compounds to be more powerful. It also found differences between labeled and measured amounts and unwanted chemicals created during processing. Another study found that products falsely labeled as “kratom extracts” contained 22 to 75 milligrams of 7-OH per gram—much more potent than a normal kratom leaf. Earlier testing also found commercial products with much more 7-OH than natural leaf. Additionally, the market fails to provide consumers with consistent health information. Even websites run by vendors following voluntary manufacturing standards scored poorly on explaining benefits and risks.

Federal rules could help address these problems by setting baselines for transparency and consumer safety. First, laws could require labels to state the 7-OH amount in each serving and package. Manufacturers could test every batch for strength, identity, contaminants, and processing chemicals before giving consumers the laboratory report. Other safeguards could include child-resistant packaging, a minimum purchasing age, warnings about dependence and mixing with alcohol or sedatives, limits on youth marketing, and reporting of serious adverse events. Scientists have proposed separate standards for natural leaf, concentrated extracts, and semisynthetic products because their chemistry and risks differ. Consumer choice depends on honest information and consistent product quality. Evidence does not establish that Schedule I control protects health better than enforceable product standards. Temporary control can become permanent, Schedule I status creates research barriers, and bans could lead to demand in unregulated markets. A legal market gives regulators a place to inspect, test, and enforce rules. The Department of Health and Human Services and the DEA should forgo temporary scheduling and work with the Food and Drug Administration and Congress on rules that keep products away from minors, hold manufacturers accountable, support research, and give adults the facts needed to make informed health decisions.